| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.34 | 0.001 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.088 | 0.002 |